CalciMedica
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
505 Coast Blvd S Ste 307, La Jolla, Cali...Phone Number
(858) 952-5500Website
www.calcimedica.comRevenue
<$5 MillionStock Symbol
CALCIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About CalciMedica
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Explore more
CalciMedica Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CalciMedica your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once CalciMedica has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on CalciMedica recently announced quarterly report
Check if CalciMedica has recently received funding, and reach out quickly before it becomes old news!
Click to see if CalciMedica had a recent Job posting/layoffs
Check out if CalciMedica is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at CalciMedica
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when CalciMedica launches new products
CalciMedica, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to CalciMedica
Compare insights from companies similar to CalciMedica, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CalciMedica is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CalciMedica is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CalciMedica.
CalciMedica financials insights
Gather financial insights about CalciMedica, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Debt
$9.2M
2011
Unspecified
$6M
Debt
$4M
2012
Debt
$13.2M
Debt
$4.6M
2013
Debt
$3M
2014
Private Equity
$2.5M
2020
Series C
$15M
2021
Series D
$21M
CalciMedica Tech Stack
A closer look at the technologies used by CalciMedica
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Finance
Person-Based
Earnings
Earnings, Finance
CalciMedica News & Media
CalciMedica (CALC) CMO awarded 91173 options at $0.585 exercise price - Stock Titan
CalciMedica’s Chief Medical Officer received 91,173 employee stock options at a $0.585 exercise price, vesting monthly over four years starting April 1, 2026, subject to a Form S-8 condition.CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ Design of pivotal program in acute pancreatitis (AP) expected in 1H 2026 JCI Insight publication of...CalciMedica’s stock drops 75% on acute kidney injury trial termination
The biopharma will now evaluate how it can safely progress Auxora’s development in AKI.CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding CalciMedica
Sign Up For FreeTo access detailed company insights
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in... Read More
